SCHEMBL4285827

SCHEMBL4285827

COc1ccc(-c2nc(CNC(=O)c3ncccc3OCC(C)C)co2)cc1OCC(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.41
CDK2 P24941 2/20 0.41
DHODH Q02127 2/20 0.41
HPGD P15428 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 2/20 0.39
ADORA2A P29274 1/20 0.39
KMT2A Q03164 3/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275349 0.98 GSK3B (0.41) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4273674 0.97 LMNA (0.42) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4275383 0.95 BRD4 (0.40) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4275012 0.93 GSK3B (0.41) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4279514 0.93 PDE4B (0.42) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4282801 0.90 HPGD (0.46) GSK3BCDK2HPGDCYP1A2CYP3A4
SCHEMBL19182630 0.88 LMNA (0.43) GSK3BCDK2DHODHHPGDCYP1A2
SCHEMBL4275305 0.88 DHODH (0.46) DHODHHPGDMAPTKMT2AHSD17B10
SCHEMBL4276064 0.88 DHODH (0.46) DHODHHPGDMAPTKMT2AHSD17B10
SCHEMBL4269836 0.85 GSK3B (0.40) GSK3BCDK2HPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 EP disclosed
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-04-10 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
EP-1954684-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2008-08-13 EP disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B GSK3B 754/4885CDK2 3134/4885DHODH 978/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 599/4885CDK2 914/4885DHODH 1127/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A GSK3B 646/4885CDK2 900/4885DHODH 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.